Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Rating of “Hold” by Brokerages

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been assigned an average recommendation of “Hold” from the five analysts that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $29.6667.

Several analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen cut Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. Finally, Zacks Research downgraded Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 13th.

Institutional Investors Weigh In On Eton Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Oberweis Asset Management Inc. bought a new stake in Eton Pharmaceuticals during the 3rd quarter worth about $4,180,000. PharVision Advisers LLC bought a new stake in Eton Pharmaceuticals during the third quarter worth about $229,000. XTX Topco Ltd acquired a new position in Eton Pharmaceuticals during the third quarter valued at approximately $530,000. Voleon Capital Management LP acquired a new position in Eton Pharmaceuticals during the third quarter valued at approximately $238,000. Finally, Quarry LP bought a new position in Eton Pharmaceuticals in the third quarter valued at approximately $37,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $16.80 on Tuesday. The firm has a market cap of $450.58 million, a P/E ratio of -67.20 and a beta of 1.17. Eton Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $23.00. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63. The firm’s 50 day moving average price is $17.04 and its two-hundred day moving average price is $16.80.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.20). The company had revenue of $22.46 million for the quarter, compared to analyst estimates of $20.47 million. Eton Pharmaceuticals had a negative return on equity of 11.32% and a negative net margin of 9.50%. On average, analysts forecast that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.